Becton Dickinson vs Medline
BDX and MDLN side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BDX and MDLN compare
Becton Dickinson is the larger company, worth 1.3 times as much as Medline ($54.0B against $42.2B).
Becton Dickinson grew revenue faster over the last twelve months (17.4% versus 11.5% for Medline).
Medline keeps more of each dollar of sales as profit, with a net margin of 4.1% compared with 4.0% at Becton Dickinson.
Becton Dickinson pays a dividend yielding 2.1%; Medline does not pay one.
Becton Dickinson scores higher on the StockData Score (13 against 5 for Medline), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BDX | MDLN |
|---|---|---|
| Size and price | ||
| Market cap | $54.0B | $42.2B |
| Share price | $198.34 | $32.12 |
| Change, 1 year | 7.7% | – |
| Change, 5 years | −18.6% | – |
| Beta (5Y) | 0.51 | – |
| Employees | 72K | 45K |
| StockData Score | ||
| Total score | 13 (better) | 5 |
| Valuation score | 2 (better) | 0 |
| Growth score | 3 (better) | 2 |
| Performance score | 3 (better) | 2 |
| Health score | 2 (better) | 1 |
| Dividend score | 3 (better) | 0 |
| Valuation | ||
| P/E | 59.9× | – |
| P/S | 2.3× | 1.5× (better) |
| P/B | 2.2× (better) | 3.6× |
| EV/EBITDA | 14.1× (better) | 18.5× |
| P/FCF | 16.9× (better) | 32.6× |
| FCF yield | 5.9% (better) | 3.1% |
| Fair value | $183.90 | $26.54 |
| Margin of safety | −7.9% (better) | −21.0% |
| Growth | ||
| Revenue growth (TTM) | 17.4% (better) | 11.5% |
| Revenue growth, 5Y average | 6.3% | – |
| Net income growth (TTM) | −40.6% | – |
| EPS growth (TTM) | −39.6% | – |
| EPS growth, 5Y average | 16.5% | – |
| Profitability | ||
| Gross margin | 46.9% (better) | 26.4% |
| Operating margin | 10.7% (better) | 7.8% |
| Net margin | 4.0% | 4.1% (better) |
| FCF margin | 13.8% (better) | 4.6% |
| Return on equity | 3.8% | 10.0% (better) |
| Return on invested capital | 5.1% | 9.6% (better) |
| Financial health | ||
| Debt / equity | 0.69 (better) | 1.09 |
| Net debt / EBITDA | 3.23 | 3.07 (better) |
| Interest coverage | 4.2× (better) | 2.3× |
| Current ratio | 0.87 | 4.33 (better) |
| Altman Z-score | 2.30 | 2.44 (better) |
| Piotroski F-score | 5 | – |
| Dividends and buybacks | ||
| Dividend yield | 2.1% | – |
| Payout ratio | 125% | – |
| Years of dividend growth | 12 | – |
| Dividend growth, 5Y average | 5.7% | – |
| Buyback yield | 4.6% (better) | 0.08% |
| Shareholder yield | 6.7% (better) | 0.08% |
| Ownership | ||
| Held by institutions | 102% | 57.1% |
| Held by insiders | 0.21% | 85.0% |
| Insider net buying, 12 months | −$2.8M (better) | −$13.4B |
| Superinvestors holding | 2 | 4 (better) |
| Short interest, % of float | 3.6% | 26.7% |
Go deeper
- BDX stock overview
- BDX income statement
- BDX valuation and score
- MDLN stock overview
- MDLN income statement
- MDLN valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.